SAGE Sage Therapeutics, Inc.

66.05
-2.105  -3%
Previous Close 68.15
Open 67.93
Price To book 7.98
Market Cap 2.47B
Shares 37,346,000
Volume 283,701
Short Ratio 5.66
Av. Daily Volume 392,644

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 2 initiation announced December 19, 2016. Part B data due 1H 2018.
SAGE-217
Major Depressive Disorder (MDD)
Phase 2 initiation announced December 13, 2016. Data from Part A data released May 9, 2017. Part B data due 2H 2017.
SAGE-217
Parkinson’s disease (PD)
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE-217
Postpartum depression (PPD)
Phase 3 data due 2H 2017.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data due 3Q 2017 - updated timeline received May 9, 2017.
SAGE-547
SRSE
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
SAGE-217
Essential tremor